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Introduction
Rhabdomyosarcoma  (RMS)  is  the  most  common  soft-tissue 
sarcoma in children and adolescents, accounting for 5–10% 
of all pediatric solid malignancies (Breitfeld and Meyer, 2005). 
RMSs resemble developing skeletal muscle, and they are broadly 
divided into two main subgroups based on their histology: alve-
olar and embryonal.
Recently, Williamson et al. (2007) showed that the gene 
encoding glypican-5 (GPC5), a member of the glypican family, 
was amplified in 20% of patients with alveolar RMS and that 
this glypican was overexpressed in all 85 RMS patients included 
in their study compared with normal muscle. Moreover, these 
authors showed that down-regulation of GPC5 expression by 
RNAi inhibits the proliferation rate of RMS cells.
Glypicans are a family of proteoglycans that are linked to 
the exocytoplasmic surface of the plasma membrane via a glyco-
sylphosphatidylinositol anchor (Filmus and Selleck, 2001; 
Song and Filmus, 2002; Filmus et al., 2008). Six glypicans have 
been identified in mammals (GPC1 to GPC6) and two in Dro-
sophila melanogaster (Dally and Dlp; Paine-Saunders et al., 
1999; Veugelers et al., 1999; Filmus et al., 2008). Like all 
proteoglycans, glypicans display a variable number of glycos-
aminoglycan (GAG) chains. The core proteins of glypicans are 
characterized by a similar size (60–70 kD) and a highly con-
served localization of 14 cysteine residues. In addition, all the 
insertion sites for the GAG chains are found within the last 60 
amino acids, placing these chains close to the cell surface (Filmus 
et al., 2008). Generally, glypicans carry heparan sulfate (HS) 
chains, but GPC5 also displays chondroitin sulfate (CS) chains 
(Saunders et al., 1997).
Glypicans regulate the signaling activity of various mor-
phogens/growth  factors,  including  Wnts  (Lin  and  Perrimon, 
1999; Tsuda et al., 1999; Ohkawara et al., 2003; Song et al., 
2005), Hedgehogs (Hh’s; Desbordes and Sanson, 2003; Lum   
et al., 2003; Han et al., 2004; Beckett et al., 2008; Gallet et al., 
2008; Yan et al., 2010), and bone morphogenic proteins (Jackson   
et al., 1997; Kreuger et al., 2004; Akiyama et al., 2008). Genetic 
and  biochemical  studies  have  shown  that  glypicans  regulate 
morphogen/growth factor signaling at the level of ligand recep-
tor interaction (Desbordes and Sanson, 2003; Song et al., 2005). 
The picture that is emerging from the recent literature is that the 
specific function of a particular glypican depends on the structural 
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features  of  that  glypican  and  on  which  growth  factors  and 
growth factor receptors are expressed by a specific cell type 
(Filmus et al., 2008).
Glypicans were first implicated in the regulation of Hh 
signaling by studies performed in Drosophila. Desbordes and 
Sanson (2003) and Lum et al. (2003) reported that Dlp (but 
not Dally) is required for optimal Hh signaling in a cell- 
autonomous manner. Epistatic experiments suggested that Dlp 
facilitates the interaction between Hh and its receptor Patched 1 
(Ptc1) at the cell surface (Desbordes and Sanson, 2003). Our 
laboratory has recently provided experimental evidence of the 
involvement of a mammalian glypican in the regulation of Hh 
signaling. We showed that GPC3 acts as a negative regulator of 
Hh activity by competing with Ptc1 for Hh binding (Capurro   
et al., 2008, 2009).
There is strong genetic evidence indicating that the activa-
tion of the Hh signaling pathway plays a causal role in the pro-
gression of RMS. First, patients with the Gorlin syndrome, in 
which the Hh pathway is activated as a result of loss-of-function 
mutations of Ptc1, display a predisposition for RMS (Hahn   
et al., 1996; Gorlin, 2004). Second, Ptc1 heterozygous mice fre-
quently develop RMS (Hahn et al., 1998). Third, a proportion of 
informative RMSs show loss of heterozygosity in the Ptc1 re-
gion (Bridge et al., 2000). In addition, the fact that many RMSs 
express Hh suggests that Hh signaling can be activated in an   
autocrine manner in these tumors (Tostar et al., 2006). The au-
thors of the study that implicated GPC5 in the progression of 
RMS  investigated  the  possibility  that  the  growth-promoting   
effect of GPC5 was the result of the ability of this glypican to 
stimulate the activity of three heparan-binding growth factors: 
FGF,  hepatocyte  growth  factor,  or Wnt1  (Williamson  et  al., 
2007). They observed that GPC5 induces a slight increase in the 
proliferation rate of an RMS cell line in the presence of each of 
these growth factors. However, the possibility that GPC5 acti-
vates Hh signaling in RMS was not investigated.
Given the fact that glypicans are known to regulate the Hh 
signaling pathway and that this signaling pathway plays a role 
in RMS, we hypothesized that GPC5 promotes RMS cell prolif-
eration by stimulating endogenous Hh activity. In this paper, we 
present experimental evidence supporting this hypothesis. In addi-
tion, we uncover the molecular basis for the differential effect 
of GPC5 and GPC3 on the signaling activity of Hh.
Results
GPC5 stimulates Hh signaling in RMS cells
As a first approach to investigate whether GPC5 stimulates Hh 
signaling in RMS cells, we studied the effect of GPC5 knock-
down on the expression of Gli1, a very well-characterized target 
of Hh signaling (Ruiz i Altaba et al., 2007). To this end, we used 
RH30, an RMS cell line that expresses high levels of GPC5 
(Williamson et al., 2007) and Hh (unpublished data). To knock 
down GPC5 expression, cells were incubated with a commer-
cially available GPC5 siRNA, which has already been used for 
this purpose (Williamson et al., 2007). Western blotting analysis 
showed that the expression of GPC5 in RH30 cells was strongly 
down-regulated by the targeting siRNA compared with cells 
Figure 1.  GPC5 siRNA inhibits proliferation and Gli1 expression in RH30 
RMS cells. Cells were treated with the indicated siRNAs for 24 h. (A) West-
ern blot analysis. 2 d after the removal of the siRNA, cells were lysed, and 
levels of GPC5 were assessed by Western blot analysis. Actin was used as 
a loading control. (B) Real-time RT-PCR. Quantitative analysis of Gli1 expres-
sion using real-time PCR was performed. Error bars represent the means of 
three independent measurements ± SD. The asterisk indicates a significant 
difference from the control (P < 0.01). (C) MTT assays were performed at 
the indicated time points. Results represent the means of quintuplicates ± SD. 
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treated with nontargeting siRNA control (Fig. 1 A). It is well 
established that most cells that produce high levels of glypicans 
display a proportion of these proteins in a nonglycanated form. 
In this regard, it should be noted that the commercially available 
anti-GPC5 antibody that was used in this study has very low 
sensitivity for the detection of glycanated GPC5. In fact, most 
antiglypican antibodies fail to detect the glycanated endogenous 
glypicans in Western blots, probably because the GAG chains 
block epitope recognition on the blotted membrane (Saunders   
et al., 1997; Veugelers et al., 1999). Thus, the Western blot in 
Fig. 1 A only shows the 65-kD GPC5 core protein. However, the 
glycanated form could be detected when high amounts of puri-
fied GPC5 were submitted to Western blot analysis (see Fig. 3 B, 
top right). The levels of Gli1 in the RH30 cells treated with the 
GPC5 siRNA or siRNA control were measured by real-time   
RT-PCR. We found that, compared with the control siRNA, the 
GPC5 siRNA significantly down-regulated Gli1 levels (Fig. 1 B). 
As previously shown by Williamson et al. (2007), we also ob-
served that down-regulation of GPC5 significantly inhibits the 
proliferation rate of the RMS cells (Fig. 1 C).
As an additional approach to investigate the impact of 
GPC5 on Hh activity in RMS cells, we assessed the effect of   
ectopic GPC5 on Hh signaling in CW9019, an RMS cell line 
that expresses low levels of GPC5, similar to normal muscle 
(Williamson et al., 2007) and Hh (unpublished data). To this 
end, CW9019 cells were transfected with a GPC5 expression 
vector or vector alone, and GPC5-overexpressing cells were 
sorted by FACS. Overexpression of GPC5 in the sorted cells 
was verified by Western blot analysis (Fig. 2 A). Ectopic GPC5 
induced a significant increase in Gli1 expression (Fig. 2 B). 
Consistent with this observation, the GPC5-transfected CW9019 
cells proliferated faster than the vector-transfected cells (Fig. 2 C). 
Significantly, the GPC5-induced stimulation of cell proliferation 
was completely abrogated by cyclopamine, a well-characterized 
inhibitor of Hh signaling (Fig. 2 C). It should be noted that   
cyclopamine also inhibited the proliferation of vector control–
transfected cells, suggesting that the Hh signaling pathway al-
ready displays a significant degree of activation in the CW9019 
cells, probably as a result of an autocrine loop. Collectively, 
these experiments indicate that GPC5 stimulates cell prolifera-
tion in RMS cells by activating Hh signaling.
We also investigated the effect of GPC5 on Hh signaling 
by using a luciferase reporter assay, in which luciferase expres-
sion is driven by an Hh-responsive promoter. Because this re-
porter assay does not work in RMS cells (unpublished data), we 
used C2C12 myoblasts that, like RMS cells, are the result of the 
malignant transformation of immature muscle cells. As shown 
in Fig. 3 A, the transient expression of GPC5 in C2C12 cells 
stimulated in a dose-dependent manner the luciferase activity 
induced by Sonic Hh (Shh) N terminus (ShhN)–containing con-
ditioned medium. This result provides additional support to the 
hypothesis that GPC5 stimulates Hh signaling.
Next, we studied the role of the GAG chains in the GPC5-
induced stimulation of Hh signaling. To this end, we generated 
a GPC5 mutant that cannot be glycanated because of the muta-
tion of the five insertion sites for the GAG chains (GPC5GAG). 
The expression of this mutant was verified by Western blot analysis 
Figure 2.  GPC5 overexpression stimulates proliferation and Gli1 expres-
sion in CW9019 RMS cells. Cells were transfected with GPC5 or control 
vector (pTracer). (A) Western blot analysis of GPC5 expression. Actin was 
used as a loading control. (B) Quantitative analysis of Gli1 expression   
using real-time RT-PCR. Error bars represent the means of three independent 
measurements ± SD. The asterisk indicates a significant difference from the 
control (P < 0.01). (C) MTT assays were performed at the indicated time 
points. Media were replaced every 24 h. Results represent the means ± 
SEM of quintuplicates. The experiment was repeated twice with similar 
results. Cyclo, cyclopamine.
of transiently transfected 293T cells. As shown in Fig. 3 B (top 
left), the GPC5GAG mutant generated a band corresponding 
to the core protein that was significantly stronger than that JCB • VOLUME 192 • NUMBER 4 • 2011   694
After removing the unbound material, cells were washed and 
lysed, and Ptc1 was immunoprecipitated. The amount of Shh 
bound to the immunoprecipitated Ptc1 was quantified by mea-
suring the AP activity in the precipitate. As shown in Fig. 4, we 
found that GPC5 significantly stimulates, in a dose-dependent 
manner, the binding of Shh to Ptc1. It should be noted that, un-
like the Hh that is produced endogenously by the RMS cells, the 
Shh-AP fusion protein is in a monomeric form. However, we 
have demonstrated that GPC5 stimulates the signaling of both 
the monomeric and oligomeric forms of Shh (Fig. S1).
We also studied the effect of the GPC5GAG mutant on 
the binding of Shh to Ptc1 following the same protocol as de-
scribed for the wild-type GPC5. We found that GPC5GAG 
cannot stimulate this binding (Fig. 4). This is consistent with the 
result of the Hh reporter assay showing that the nonglycanated 
GPC5 cannot stimulate Hh signaling (Fig. 3 A).
GPC5 binds to Shh
Next, we investigated the mechanism by which GPC5 stimu-
lates the binding of Hh to Ptc1. We hypothesized that GPC5 can 
facilitate/stabilize the interaction of Hh with Ptc1. If this hy-
pothesis were correct, it would be expected that GPC5 interacts 
with both Hh and Ptc1. Our laboratory has already demonstrated 
that Shh binds to GPC3 with high affinity (Capurro et al., 2008). 
First, we investigated whether GPC5 interacts with Shh. As an 
initial approach, we performed surface plasmon resonance 
(SPR) analysis. To this end, a GPC5-AP fusion protein was pu-
rified from 293T cells and attached to a Biacore sensor chip. 
The analysis showed that Shh binds to GPC5-AP with a Kd of 
310 ± 60 nM (Fig. 5 A, top; and Table S1). We also performed 
corresponding to wild-type GPC5, despite the fact that the 
transfected cells produced similar levels of the respective tran-
scripts (Fig. 3 B, bottom). This is most likely because a large 
proportion of the wild-type GPC5 is glycanated and because the 
glycanated form cannot be detected in the Western blot as a   
result of the low sensitivity of the antibody. To verify this, we 
concentrated the glycanated GPC5 from the lysates of trans-
fected cells by anion-exchange chromatography, and the con-
centrated material was submitted to Western blot analysis. The 
glycanated GPC5 could then be detected as a high molecular 
mass smear (Fig. 3 B, top right). As expected, no signal was de-
tected in the material purified in the same way from the lysates 
of the cells transfected with the GPC5GAG mutant because 
this mutant does not bind to the DEAE-Sepharose.
We also studied the effect of GPC5GAG on Hh signal-
ing by using the same Hh reporter assay as used for wild-type 
GPC5. As shown in Fig. 3 A, the nonglycanated GPC5 did   
not stimulate Hh signaling, indicating that the GAG chains   
are essential for the GPC5-induced stimulation of this sig-
naling pathway.
GPC5 promotes the binding of Shh to Ptc1
Next, we investigated the mechanism by which GPC5 stimu-
lates Hh signaling in RMS cells. Based on the experiments in 
Drosophila that showed that Dlp promotes Hh activity by acting 
upstream or at the level of Ptc1 (Desbordes and Sanson, 2003), 
we hypothesized that GPC5 can stimulate the interaction be-
tween Hh and Ptc1. To test this hypothesis, we transiently trans-
fected GPC5 into 293T cells. 2 d after transfection, cells were 
incubated with an Shh-AP fusion protein for 2.5 h at 4°C.   
Figure 3.  GPC5 stimulates Shh-induced signaling. (A) Hh reporter assay. Mouse myoblast C2C12 cells were transfected with the indicated vectors 
along with a luciferase reporter and -galactosidase. An Hh reporter assay was then performed. Bars represent normalized fold stimulation of luciferase 
activity induced by ShhN (means ± SD of triplicates). The experiment was repeated three times with similar results. (B) Transient expression of GPC5 and 
GPC5GAG (GAG). 293T cells were transiently transfected with the indicated vectors. 2 d after transfection, the expression of the GPC5 variants was 
assessed by Western blot analysis of whole cell lysates (top left), the DEAE-purified material from the lysates (top right), or by RT-PCR (bottom). (top) Numbers 
on the left represent molecular mass markers. Actin was used as a control of the amount of RNA. Fr, fraction.695 Glypican-5 activates Hedgehog signaling • Li et al.
Western blot analysis. We found that Ptc1 coimmunoprecipitated 
with wild-type GPC5 but not with GPC5GAG (Fig. 6 A). 
Next, we studied the GPC5–Ptc1 interaction by performing   
a  cell-binding  assay.  Ptc1-  or  control  vector–transfected 
293T cells were incubated with conditioned media contain-
ing equal concentrations of a GPC5-AP fusion protein or a 
GPC5GAG-AP fusion protein at 4°C for 2 h. After washing 
with cold PBS, cells were lysed, and the cell-bound AP activ-
ity was measured. As shown in Fig. 6 B, we found that the 
binding of GPC5-AP to the Ptc1-transfected cells is much 
higher than that to the vector control–transfected cells. Consis-
tent with the coimmunoprecipitation results, GPC5GAG-AP 
did not bind to the Ptc1-transfected cells. We also studied   
the interaction between GPC5 and Ptc1 by a pull-down assay. 
To this end, 293T cells were transiently transfected with an 
expression  vector  for  HA  (hemagglutinin-A)-tagged  Ptc1, 
cells were lysed, and the lysate was mixed with beads covered 
with an anti-HA antibody. The beads were then incubated 
with conditioned media containing equal concentrations of a 
GPC5-AP fusion protein or a GPC5GAG-AP fusion protein. 
After washing, the amount of AP that remained bound to the 
beads was measured. We found that although there was a   
significant  binding  of  wild-type  GPC5  to  the  beads,  the 
GPC5GAG  mutant  did  not  show  any  detectable  binding 
(Fig. 6 C). This result is consistent with the result of the co-
immunoprecipitation. Next, we tried to estimate the affinity 
of the GPC5–Ptc1 interaction by performing the pull-down 
assay with various concentrations of GPC5-AP. To measure 
the concentration of GPC5-AP in the conditioned media, we 
performed a comparative Western blot using different amounts 
of purified GPC5GAG (unpublished data). The Scatchard 
analysis showed that GPC5 interacts with Ptc1 with a Kd of   
37 nM (Fig. 6 D). From these experiments, we conclude that 
SPR analysis of the interaction of Shh with GPC5-AP purified 
from the RH30 RMS cell line. In this case, the calculated Kd 
was 1,530 ± 625 nM (unpublished data). Notably, the affinity   
of the GPC5–Shh interactions is significantly lower than that of 
the interaction between GPC3 and Shh. Previously, we have 
shown that the high affinity interaction of Shh with GPC3 is 
mediated by the core protein (Capurro et al., 2008). However, 
when the GAG chains of GPC5-AP were removed by digestion 
with GAG-degrading enzymes, the binding of Shh to GPC5-AP 
was dramatically inhibited (Fig. 5 A, bottom), indicating that 
the GAG chains play a key role in the binding. We also investi-
gated the interaction between GPC5 and Shh in the context of 
intact cells. To this end, 293T cells were transiently transfected 
with GPC5 or GPC5GAG, and the transfected cells were incu-
bated with an Shh-AP fusion protein. Unbound material was re-
moved, cells were washed and lysed, and GPC5 or GPC5GAG 
was immunoprecipitated. The level of AP activity in the immuno-
precipitates  was  then  measured.  Immunoprecipitates  from 
cells transfected with vector alone were used as negative con-
trols. We  found  significant  binding  of  Shh-AP  to  wild-type 
GPC5, but the binding of Shh to the nonglycanated mutant 
(GAG)  was  significantly  lower  than  that  of  the  wild-type 
GPC5 (Fig. 5 B). Collectively, the SPR analysis and binding ex-
periments indicate that GPC5 binds to Shh mainly through the 
GAG chains.
GPC5 binds to Ptc1
As an initial approach to investigate the interaction of GPC5 
with Ptc1, we performed a coimmunoprecipitation assay. Ex-
pression vectors for Ptc1 and for wild-type GPC5 or GPC5GAG 
were transiently transfected into 293T cells. Cells were then 
lysed, GPC5 or GPC5GAG was immunoprecipitated, and 
the presence of Ptc1 in the precipitated material was assessed by 
Figure  4.  GPC5  promotes  Shh  binding  to 
Ptc1.  293T  cells  were  transiently  transfected 
with increasing amounts of the indicated ex-
pression vectors or empty vector (pTracer). 48 h   
after  transfection,  the  cells  were  incubated 
with  Shh-AP  or  AP  at  4°C  for  2.5  h.  After 
washing,  endogenous  Ptc1  was  immuno-
precipitated  (IP), and the amount of Shh-AP 
bound  to  the  immunoprecipitated  Ptc1  was 
determined by measuring AP activity. Bars rep-
resent the relative amount of Shh-AP bound to 
Ptc1 after subtraction of the binding measured 
for AP alone (means ± SD of triplicates). The 
corresponding immunoprecipitated Ptc1 from 
each  sample  was  assessed  by  Western  blot 
(WB) analysis (bottom).JCB • VOLUME 192 • NUMBER 4 • 2011   696
The binding of GPC5 to Ptc1 is mediated 
by both HS and CS
We have previously shown that GPC3 does not bind to Ptc1 
(Capurro et al., 2008). Thus, the results shown in Fig. 6 demon-
strating that GPC5 binds to Ptc1 through its GAG chains 
strongly suggest that the differential binding of these two glypi-
cans is caused by differences in the GAG chains. Because it has 
been previously shown that, unlike GPC3, which only displays 
HS chains (Filmus et al., 1995), GPC5 also carries CS chains 
(Saunders et al., 1997), we decided to study whether the binding 
of GPC5 to Ptc1 is mediated by the CS chains. First, we tried   
to confirm that endogenous GPC5 from RMS cells carries CS 
chains. To this end, we partially purified GPC5 from RH30 cells 
by anion-exchange chromatography. Aliquots of the purified 
material were then digested with heparitinase (HSase) II, which 
specifically cleaves HS chains, or chondroitinase (CSase) ABC, 
which specifically cleaves CS chains. We also digested another 
aliquot with both enzymes together. The digested material was 
then analyzed by Western blotting with an anti-GPC5 antibody. 
Fig. 8 A shows that no bands or smears were seen in the undi-
gested material. This is expected given the fact that the anti-
GPC5 antibody has low sensitivity for the glycanated GPC5, 
and the GPC5 core protein does not bind to the DEAE-Sepharose. 
On the other hand, a single band corresponding to the GPC5 
GPC5 binds to Ptc1 with high affinity and that the GAG chains 
are essential for this interaction.
GPC5 can be found in the ciliary membrane
Recent studies have shown that the primary cilium is required to 
trigger Hh signaling and that the interaction of Hh with Ptc1 occurs 
at the ciliary membrane (Rohatgi et al., 2007; Kiprilov et al., 2008; 
Milenkovic  et  al.,  2009).  We  decided  therefore  to  investigate 
whether GPC5 can also be found at the ciliary membrane. To this 
end, NIH 3T3 cells were transfected with GPC5 or GPC5GAG 
and stained with antibodies against GPC5 and acetylated tubulin, a 
marker of primary cilia. As shown in Fig. 7 A, the GPC5 antibody 
strongly stained the primary cilium. In contrast, a very low level of 
staining was observed in GPC5GAG-transfected cells. Quantifi-
cation of the cilia-specific immunofluorescence confirmed the dif-
ferential localization of GPC5 and the nonglycanated mutant   
(Fig. 7 B). We also investigated whether GPC3 can be found in 
cilia. As shown in Fig. 7 C, we could not detect any staining in cilia 
of GPC3-transfected NIH 3T3 cells. We also investigated the local-
ization of endogenous GPC5 by staining the RMS cell line RH30. 
Although primary cilia are difficult to detect in rapidly growing 
RH30 cells, a low proportion of cilium-carrying cells could be de-
tected after serum starvation for 48 h. As shown in Fig. 7 D, the 
GPC5 antibody strongly stained the primary cilia of RH30 cells.
Figure 5.  Shh binds to GPC5. (A) SPR analysis of the GPC5–Shh interaction. Various concentrations of Shh (bottom to top: 112.5, 225, 450, 900, and 
1,800 nM) were used for the interaction assay with GPC5-AP (top) or deglycanated GPC5-AP (bottom). n = 1. (B) Binding of Shh-AP to GPC5-transfected 
293T cells. Cells were transfected with GPC5, GPC5GAG (GAG), or control vector (pTracer) and were incubated with Shh-AP or AP alone at 4°C for 2 h. 
Cells were lysed, GPC5 was immunoprecipitated, and the AP activity in the precipitate was measured. Bars represent the relative amounts of Shh-AP bound 
to GPC5 after subtraction of the binding measured for AP alone (means ± SD of duplicates). RU, response unit.697 Glypican-5 activates Hedgehog signaling • Li et al.
by anion-exchange chromatography and affinity chromatogra-
phy and was submitted to treatment with HSase, CSase, or both 
enzymes to confirm that the fusion protein carries a proportion 
of CS and HS that is similar to that of the endogenous GPC5. 
The digested material was analyzed by Western blotting. This 
analysis showed that, like the endogenous GPC5, most of the puri-
fied GPC5-AP fusion protein carries both HS and CS (Fig. 8 B).   
It should also be noted that the smear corresponding to the gly-
canated GPC5-AP could be detected by the anti-GPC5 antibody. 
This suggests that there might be some differential accessi-
bility to the epitope recognized by the anti-GPC5 antibody in 
the wild-type GPC5 purified from cell lysates compared with 
the GPC5-AP purified from conditioned media. This is prob-
ably because GPC5-AP has been separated from other pro-
teoglycans by the affinity chromatography, and the epitope 
core protein was detected after digestion with HSase, suggest-
ing that a proportion of GPC5 in RMS cells only displays HS. 
No bands or smears were seen after digestion with CSase, indi-
cating that most or all GPC5 from RMS cells display HS chains. 
The digestion with both enzymes generated a band correspond-
ing to the core protein that was significantly more intense than 
that generated after digestion with HSase alone, indicating that 
a significant proportion of GPC5 in RMS cells carries both   
HS and CS.
To investigate the role of the CS chains in the binding of 
GPC5 to Ptc1, relatively large amounts of purified GPC5 are re-
quired.  To  facilitate  the  purification  of  larger  quantities  of 
GPC5, we transiently transfected RMS cells with an expression 
vector for a GPC5-AP fusion protein, which is secreted to the 
conditioned medium. GPC5-AP was purified from the medium 
Figure 6.  Ptc1 binds to GPC5. (A) Coimmunoprecipitation. 293T cells were transfected with the indicated plasmids, and GPC5 was immunoprecipi-
tated (IP). The presence of Ptc1 in the precipitated material was then assessed by Western blotting (WB; top). The expression levels of Ptc1 (middle) and 
GPC5 (bottom) in the transfected cells were verified by Western blotting. Murine stem cell virus (MSCV) and elongation factor (EF) indicate expression 
vectors alone. (B) Cell-binding assay. 293T cells were transfected with Ptc1 or control vector (murine stem cell virus) and were incubated with GPC5-AP, 
GPC5GAG-AP (GAG-AP), or AP alone at 4°C for 2 h. Cells were then lysed, and the AP activity of aliquots of cell lysates containing the same amount of 
protein was measured. Bars represent the relative amount of GPC5-AP bound to Ptc1 after subtraction of the binding measured for AP alone. (C) Pull-down 
assay. Interactions of Ptc1 with Shh-AP (positive control), GPC5-AP, GPC5GAG-AP, or AP only were investigated using a pull-down assay. The experiment 
was repeated twice with similar results. (D) Affinity measurement. The affinity of the interaction between Ptc1 and GPC5-AP was measured using a binding 
assay. The binding data were analyzed by Scatchard plotting (inset). Error bars represent the means of duplicates ± SD.JCB • VOLUME 192 • NUMBER 4 • 2011   698
The HS chains of GPC5 display a higher 
degree of sulfation than those of GPC3
It is well established that the binding specificity of the HS chains 
is predominantly determined by the degree and type of sulfation 
(Bishop et al., 2007; Gorsi and Stringer, 2007). Thus, the fact 
that the binding of GPC5 to Ptc1 is mostly mediated by the HS 
chains and that, unlike GPC5, GPC3 does not bind to Ptc1 
(Capurro et al., 2008) strongly suggests that the HS chains of 
GPC5 display a different sulfation pattern than those of GPC3. 
We decided, therefore, to compare the sulfation profile of these 
two glypicans. The degree of sulfation of GAG chains produced 
by a given cell type is determined, at least in part, by the levels 
of sulfotransferases and sulfatases expressed by this cell type 
(Gorsi and Stringer, 2007). In this regard, it should be noted 
that, so far, the GPC5 and GPC3 that we used to establish the 
differential  binding  to  Ptc1  were  produced  in  different  cell 
types: GPC3 was purified from transfected 293T cells (Capurro 
et  al.,  2008),  and  GPC5  was  purified  from  RMS  cells  (this 
study). We considered, therefore, that it was important to com-
pare the sulfation of the HS chains from GPC3 and GPC5 that 
were expressed in the same cell type. Because GPC3 is not ex-
pressed by RMS cells, we decided to compare GPC5 and GPC3 
produced in NIH 3T3 cells. We have previously used these cells 
recognized by the anti-GPC5 is more accessible in the Western 
blot membrane.
To investigate the role of the HS and CS chains in the 
binding of GPC5 to Ptc1, aliquots of the GPC5-AP fusion pro-
tein were digested with HSase, CSase, or both enzymes to-
gether, and a pull-down assay was performed with undigested 
and digested fusion protein. We found that the digestion of the 
HS chains strongly inhibited the binding of GPC5-AP to Ptc1. 
The effect of CSase was significantly less pronounced (Fig. 8 C). 
Consistent with this result, we found that the binding of GPC5-AP 
to Ptc1 is strongly inhibited by heparan but partially reduced   
by CS-A from bovine trachea (Sigma-Aldrich), which mostly 
contains the monosulfated disaccharide GlcA1–3GaINAc(4-
O-sulfate), the main component of mammalian CS (Fig. 8 D). 
Interestingly, the binding of GPC5-AP to Ptc1 was strongly in-
hibited by the highly sulfated CS-E from squid cartilage, con-
taining >60% of GlcA1–3GaINAc(4,6-O-disulfate), which is 
not normally found in mammals (Sugahara et al., 2003). These 
data suggest that sulfation plays an important role in the binding 
of the GAG chains of GPC5 to Ptc1. Collectively, our results in-
dicate that the binding of GPC5 to Ptc1 is mostly mediated by 
the HS chains and that the CS chains contribute to the binding 
when the HS chains are present.
Figure 7.  GPC5 localizes to the primary cilium. (A) NIH 3T3 cells transfected with the indicated vectors were stained with the indicated antibodies.   
(B) Ratio of fluorescence intensity in/out of cilia of NIH 3T3 cells transfected with GPC5 or GPC5GAG. Error bars represent the means of seven cells ± SD. 
(C) NIH 3T3 cells transfected with GPC3 were stained with the indicated antibodies. (D) Immunofluorescence of endogenous GPC5 in the RMS cell line 
RH30. In the merged pictures, yellow indicates a colocalization of GPC5 with cilia. Cilium is indicated by arrows.699 Glypican-5 activates Hedgehog signaling • Li et al.
We then compared the binding of the two fusion proteins to Ptc1 
by a pull-down assay. We found that GPC5-AP purified from 
NIH 3T3 cells displays a much higher capacity to bind Ptc1 than 
GPC3-AP (Fig. 9 C). Furthermore, as we showed for the RH30 
cells, we found that most of the binding of GPC5-AP to Ptc1 is 
mediated by the HS chains and that the CS chains contribute to 
the binding when the HS chains are present (Fig. 9 D).
Having shown that GPC5 and GPC3 expressed in NIH 
3T3 cells display differential binding to Ptc1, we compared 
the sulfation profile of the HS chains from both glypicans in 
these cells. To this end, the purified glypicans were digested 
with a mixture of HSase I and III. The disaccharides generated 
by this digestion were labeled with 2-aminobenzamide (2AB) 
and separated by anion-exchange HPLC. The identity of each 
peak was confirmed by comparing the position of the eluted 
peaks with 2AB-labeled standard HS disaccharides (Fig. 9 E). 
The quantification of the disaccharides is shown in Fig. 9 F. 
According to the chromatogram, the HS of both GPC3-AP   
and GPC5-AP contain HexUA-GlcNAc, HexUA-GlcN(2- 
N-sulfate),  HexUA-GlcNAc(6-O-sulfate),  HexUA-GlcN(2-
N-,6-O-disulfate),  HexUA(2-O-sulfate)-GlcN(2-N-sulfate),   
to show that GPC3 inhibits Hh signaling (Capurro et al., 2008). 
We first investigated whether, like in RMS cells, GPC5 stimu-
lates Hh signaling in NIH 3T3 cells. To this end, we performed 
an Hh reporter assay. We found that GPC5 strongly stimulates, 
in a dose-dependent manner, Hh signaling (Fig. 9 A). As a con-
trol, we verified that in the same experimental conditions GPC3 
inhibits Hh signaling. In addition, we tested the effect of the 
GPC5GAG mutant in the reporter assay. As we showed for 
C2C12 cells, we observed that this mutant does not stimulate 
Hh signaling in NIH 3T3 cells (Fig. 9 A). Next, we investigated 
whether GPC3 and GPC5 produced in NIH 3T3 display a simi-
lar type of GAG chains as the cells that were previously used to 
demonstrate the differential binding of these two glypicans to 
Ptc1. To this end, NIH 3T3 cells were transiently transfected 
with the GPC5-AP and GPC3-AP fusion proteins. These pro-
teins were then purified from the transfected cells as described 
in Materials and methods and were digested with HSase, CSase, 
or both enzymes together. The digested products were then ana-
lyzed by Western blotting. As shown in Fig. 9 B, we found that, 
as previously observed in other cell types, GPC3 displays HS 
chains, and GPC5 displays a mixture of both HS and CS.   
Figure 8.  GPC5 binds to Ptc1 through its GAG chains. (A) Analysis of the GAG chains of GPC5. Endogenous GPC5 was partially purified from RH30 
cells using a DEAE-Sepharose column, digested with heparitinase II (HSase), chondroitinase ABC (CSase), or both enzymes together, and the digests were 
submitted to Western blot (WB) analysis. (B) Analysis of the GAG chains of GPC5-AP. GPC5-AP was purified from transiently transfected RH30 cells. The 
purified GPC5 was digested with the indicated enzymes, and the digests were submitted to Western blot analysis. (C) GPC5-AP–Ptc1-binding assay. An 
aliquot of each sample from B was used to perform a pull-down assay as described in Fig. 6 C. The experiment was repeated twice with similar results. 
No-En, no enzyme (undigested GPC5-AP). (D) Effect of various GAGs on GPC5–Ptc1 binding. A pull-down assay with undigested GPC5 was performed 
in the presence of the indicated concentrations of heparan (Hep), chondroitin sulfate A (CS-A), or chondroitin sulfate E (CS-E). Error bars represent means 
of duplicates ± SD.JCB • VOLUME 192 • NUMBER 4 • 2011   700
we conclude that GPC5-AP displays a much higher proportion 
of sulfated disaccharides. Because the binding capacity of a   
given GAG chain is mostly determined by the degree of sulfation, 
this result strongly suggests that the higher sulfation of the HS 
chains of GPC5 is responsible, at least in part, for the larger bind-
ing capacity of GPC5 to Ptc1 compared with that of GPC3.
Discussion
In this study, we show that GPC5 stimulates the proliferation of 
RMS cells by activating Hh signaling. Because GPC5 is over-
expressed in RMS (Williamson et al., 2007), this work uncovers 
and HexUA(2-O-sulfate)-GlcN(2-N-,6-O-disulfate) in vary-
ing  proportions  (HexUA  represents  4-deoxy-l-threohex-4- 
enepyranosyluronic acid). Although unsulfated HexUA-GlcNAc 
is  the  major  disaccharide  in  both  preparations,  the  propor-
tion of this disaccharide in GPC3-AP is much higher than in   
GPC5-AP. Conversely, the proportion of sulfated disaccharides 
is significantly higher in the HS chains purified from GPC5-AP.   
We  have  also  compared  the  disaccharide  composition  of   
GPC3-AP and GPC5-AP purified from transiently transfected 
RH30 RMS cells. As in the case of NIH 3T3 cells, we also found 
a significantly higher proportion of sulfated disaccharides in the 
HS chains extracted from GPC5-AP (Fig. S2). Consequently, 
Figure 9.  The HS chains of GPC5 are more sulfated than those of GPC3. (A) Hh reporter assay. NIH 3T3 cells were transfected with the indicated ex-
pression vectors or empty vectors (pTracer and elongation factor [EF]), and a transient luciferase reporter assay was performed as described in Fig. 3 A.   
Results represent the means ± SD of triplicates. (B) Analysis of the GAG chains. GPC3-AP or GPC5-AP was purified from transiently transfected NIH   
3T3 cells, digested with the indicated enzymes, and analyzed by Western blotting. (C) Comparative binding of GPC3 or GPC5 to Ptc1. GPC3-AP or 
GPC5-AP were purified from the indicated transiently transfected cells, and their binding to Ptc1 was assessed by a pull-down assay. Error bars represent 
the means of duplicates ± SD. The experiment was repeated twice with similar results. (D) The role of the GAG chains of GPC5 from NIH 3T3 cells in its 
binding to Ptc1. GPC5-AP purified from NIH 3T3 cells was digested with the indicated enzymes, and the binding of the digested GPC5 samples to Ptc1 
was assessed by a pull-down assay as described in Fig. 6 C. Error bars represent the means of duplicates ± SD. The experiment was repeated twice with 
similar results. (E) Disaccharide analysis of the HS chains. Purified GPC3-AP (top) and GPC5-AP (bottom) were digested with HSases, and the digested 
material was analyzed by HPLC. The elution positions of authentic 2AB disaccharide standards derived from HS are indicated by numbered arrows (top): 
(1) HexUA-GlcNAc (0S), (2) HexUA-GlcNAc(6-O-sulfate) (6S), (3) HexUA-GlcN(2-N-sulfate) (NS), (4) HexUA-GlcN(2-N-,6-O-disulfate) (NS,6S),   
(5) HexUA(2-O-sulfate)-GlcN(2-N-sulfate) (NS,2S), and (6) HexUA(2-O-sulfate)-GlcN(2-N-,6-O-disulfate) (TriS). (F) Bar graph displaying the results of the 
disaccharide analysis. n = 1.701 Glypican-5 activates Hedgehog signaling • Li et al.
GPC5-transfected cells has the same Hh activity in the Gli1 re-
porter  assay  than  conditioned  medium  from  vector  control–
transfected cells (unpublished data).
Williams et al. (2010) have recently reported that GPC5 
cannot rescue the inhibition of Hh signaling induced by dlp 
RNAi in Drosophila cells. These results are apparently contra-
dictory with our findings. It should be noted, however, that Dro-
sophila cells do not have cilia. In addition, the authors of this 
study used an expression vector in which the GPC5 cDNA had 
a HA tag at the N terminus. We have observed that this tag dra-
matically inhibits glycanation of GPC5 (unpublished data). In 
fact, the Western blot analysis of GPC5 included in the study by 
Williams et al. (2010) shows a poorly glycanated GPC5, with 
an apparent molecular mass that is not larger than that cor-
responding to the core protein. As we show here, GPC5 glycana-
tion is essential for its ability to activate Hh signaling.
We have previously reported that GPC3 acts as an inhibitor 
of Hh activity by competing with Ptc1 for Hh binding (Capurro 
et al., 2008, 2009). Thus, one important finding of this study is 
that two members of the glypican family can display opposite 
roles in the regulation of Hh signaling. We also uncover here the 
molecular basis for the differential role of GPC3 and GPC5 in 
the regulation of Hh activity by demonstrating that, unlike 
GPC3, GPC5 can interact with Ptc1. Interestingly, this inter-
action is mediated by the GAG chains. This GAG-mediated inter-
action of GPC5 with Ptc1 was observed not only with GPC5 
purified from RMS cells but also with GPC5 purified from non-
malignant  NIH  3T3  fibroblasts.  Because  GPC5  displays  CS 
chains and GPC3 does not, we first hypothesized that the CSs 
are responsible for the differential interaction. However, binding 
experiments after digestion with HSase and CSase showed that 
the interaction between GPC5 and Ptc1 is mostly mediated by 
the HS chains, although the CS chains can also bind to Ptc1 and 
contribute to the interaction when the HS chains are present.   
In this regard, our results are similar to those reported by Deepa 
et al. (2004), who showed that basic FGF interacts more effi-
ciently with syndecan-4 when this proteoglycan carries CS in 
addition to HS. Because both GPC5 and GPC3 display HS 
chains and the sulfation pattern is an important determinant of 
the binding properties of HS, we then hypothesized that this pat-
tern should be different in these two glypicans. Indeed, as shown 
in Fig. 9, we found that the HS chains of GPC5 display a signifi-
cantly higher degree of sulfation than those of GPC3 obtained 
from the same cell type. Differential sulfation of proteoglycans 
that are produced by the same cell line has already been reported 
(Tveit et al., 2005). It is possible that, in certain cell types, there 
are different kinds of complexes that contain the enzymes in-
volved in GAG synthesis (gagosomes) and that the different   
proteoglycan core proteins are targeted to specific gagosomes   
(Victor et al., 2009). It should also be noted that, at this point in 
time, we cannot discard the possibility that the fact that GPC5 
displays more GAG chains than GPC3 also contributes to the 
differential binding to Ptc1. The length of the HS chains or their 
fine structure could also be contributing factors.
Another important finding of this study is that GPC5 can 
localize to cilia. This finding is consistent with our results show-
ing that GPC5 interacts with Ptc1. Currently the molecular   
a novel mechanism by which Hh signaling can be activated in 
this malignancy. In addition, our results strongly suggest that 
GPC5 promotes this signaling pathway at the cell surface by   
facilitating/stabilizing the interaction between Hh and Ptc1. 
Other proteins that stimulate Hh signaling at the cell surface 
level have already been described, including Cdo, Boc, and 
Gas1 (Zhang et al., 2006; Allen et al., 2007; Jiang and Hui, 
2008; Varjosalo and Taipale, 2008). Although these proteins 
bind to Hh, the precise mechanism by which they stimulate Hh 
signaling remains unknown. Given the importance of this sig-
naling pathway in the regulation of differentiation and morpho-
genesis during development in many tissues, the existence of 
several membrane proteins that modulate Hh is not surprising.
As discussed in the Introduction, it has been previously 
shown that Dlp, one of the Drosophila glypicans, stimulates Hh 
signaling  (Desbordes  and  Sanson,  2003;  Lum  et  al.,  2003).   
Although the precise mechanism of this stimulation has not 
been characterized, it has been proposed that Dlp acts as an Hh 
coreceptor (Gallet et al., 2008; Yan et al., 2010). It seems there-
fore that, in the context of Hh signaling, GPC5 behaves func-
tionally like Dlp. However, our results show a clear structural 
difference between GPC5 and Dlp in the context of Hh signal-
ing: although we found that the GAG chains are essential for 
GPC5-induced stimulation of Hh signaling, Yan et al. (2010) 
reported that the GAG chains are not required for Dlp function. 
This difference could be because the Dlp core protein interacts 
with Hh (Yan et al., 2010), whereas that of GPC5 does not.   
In this regard, it is interesting to note that Hh interacts with the 
core proteins of two glypicans that are cleaved by convertases 
(GPC3 and Dlp) and that GPC5 is not cleaved by such endo-
proteases (Eugster et al., 2007).
The idea that proteoglycans can act as coreceptors was 
first proposed to explain the stimulatory role of these proteins in 
FGF signaling (Gallagher, 1994). As in the case of GPC5 and 
Hh, the role of proteoglycans in the context of FGF signaling is 
mediated by their HS chains, which can interact simultaneously 
with both the ligand and the receptor (Pellegrini et al., 2000). 
However, unlike the FGF case, we found that soluble heparin 
does not mimic the Hh stimulatory activity of the proteoglycan 
(Fig. S3). This result suggests that the core protein of GPC5 
plays an essential role. One possibility is that the GAG chains 
have to be displayed in a specific relative position in the context 
of the Hh–Ptc1 complex for a productive interaction and that 
the core protein of GPC5 plays a critical role in positioning the 
GAG chains in the context of the ligand receptor complex.
Recent work in Drosophila has demonstrated that Hh has 
to form large oligomeric clusters for long-range signaling and 
that cell surface HS proteoglycans play a critical role in the for-
mation of these oligomers (Vyas et al., 2008). It could therefore 
be suggested that GPC5 might also increase Hh signaling by 
stimulating cluster formation. However, in the signaling experi-
ments described in Figs. 3 and 9, we only tested the effect of 
GPC5 in the context of autocrine or paracrine signaling. In this 
context, monomeric Hh has a similar signaling strength than the 
oligomerized form (Vyas et al., 2008), suggesting that a poten-
tial GPC5-induced oligomerization will have no impact on sig-
naling. In fact, we have observed that conditioned medium from JCB • VOLUME 192 • NUMBER 4 • 2011   702
GPC5GAG cDNAs into the BspE1 site of the pAP-Tag2 vector (Gene-
Hunter Corporation). The other expression vectors used in this study (Shh, 
ShhN, GPC3, and HA-tagged Ptc1) were previously described (Capurro   
et al., 2008).
Generation of the GPC5-overexpressing RMS cell line CW9019
CW9019 cells were transfected with an expression vector containing the 
full-length wild-type GPC5 cDNA and a selectable marker or with the se-
lectable vector alone (pTracer). The transfections were performed by using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instruc-
tions. After selection, cells were expanded and stained with the anti-GPC5 
mAb MAB2607 (R&D Systems) and an FITC-conjugated secondary anti-
body. GPC5-overexpressing cells were then isolated by FACS.
siRNA treatment
RH30 cells were plated at 2 × 10
5 cells per well on 6-well tissue culture 
dishes in RPMI 1640 containing 10% FBS without antibiotics. The next day, 
the cells were transfected with 100-nM SMARTpool siRNAs for GPC5 or 
nontargeting siRNA (Thermo Fisher Scientific) by using Lipofectamine 2000.
Cell proliferation assay
Cells were plated at 3,000 cells per well on 96-well tissue culture plates in 
RPMI 1640 containing 1% FBS, and cell numbers were assessed at the in-
dicated time points (Figs. 1 C and 2 C) using the MTT assay. In brief, 5 µl 
MTT stock solution containing 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide in water was added to each well and incu-
bated at 37°C for 4 h. After removing the medium, 100 µl DMSO was 
added into each well to dissolve the formazan by pipetting up and down 
several times, and then the absorbance was measured at 570 nm. Each 
experiment was performed at least three times by quintuplicates.
Real-time RT-PCR
Total mRNA was extracted from cells using the TRIZOL reagent (Invitrogen) 
according to the manufacturer’s instructions. The mRNA was then used as 
a template to prepare cDNA using Superscript II Reverse Transcriptase and 
oligo(dT)12–18 primers (Invitrogen). Quantification of Gli1 mRNA expres-
sion was performed on a real-time PCR instrument (LightCycler 3.5; Roche) 
using SYBR green (QuantiTect; QIAGEN). Sequences of the oligonucleo-
tide primers used for human Gli1 and -actin are as follows: Gli1 forward, 
5-AGGGAGGAAAGCAGACTGAC-3,  and  reverse,  5-CCAGTCATTTC-
CACACCACT-3;  and  -actin  forward,  5-TTCTACAATGAGCTGCG-
TGTG-3, and reverse, 5-GGGGTGTTGAAGGTCTCAAA-3. Values for 
each sample were normalized by the level of -actin in a parallel RNA 
sample. Each RNA preparation was analyzed in triplicate. To express val-
ues as a percentage, the control value was set at 100%. All error bars rep-
resent SDs based on the means of three independent trials. Probability of a 
significant difference between two values was determined by a paired two-
tailed Student’s t test. Values were considered to be statistically significant 
when P < 0.05.
Purification of glypicans
Cell surface–anchored GPC5 was purified by anion-exchange chromatog-
raphy on DEAE-Sepharose (GE Healthcare) as previously described (Herndon 
and Lander, 1990) except that the concentration of NaCl in the elution buffer 
was increased to 2 M. Secreted AP-tagged glypicans were purified from 
conditioned media by two successive steps: first, anion-exchange chroma-
tography on DEAE-Sepharose and, second, affinity chromatography with 
the anti-AP mAb coupled to agarose (Sigma-Aldrich). In brief, the DEAE-
Sepharose gel was added to the conditioned medium and incubated at 
4°C for 4 h. The suspension was then collected in an empty column and 
washed with 0.2-M NaCl in 50-mM phosphate buffer, pH 6.5, and the 
bound material was eluted with 2-M NaCl in 50-mM phosphate buffer, pH 
6.5. The eluate was diluted fourfold with H2O and loaded on a column 
containing anti-AP agarose. After washing the column with 0.5-M NaCl in 
50-mM Tris buffer (first wash at pH 8.0 and second wash at pH 9.0), the 
AP-tagged glypican was eluted with 100-mM triethylamine and was imme-
diately neutralized by 1-M NaH2PO4. Finally, all glypican preparations 
were desalted by using Microcon YM-10 (Millipore).
Hh reporter assay
Cells were seeded into 6-well plates and cotransfected with a reporter 
plasmid in which luciferase expression is driven by a promoter containing 
Gli1-binding sequences (Capurro et al., 2008) and other indicated plas-
mids. 1 d after transfection, cells were transferred to 24-well plates, and 
the following day, ShhN- or control-conditioned medium (diluted 1:10 in 
determinants of cilia localization are not clearly understood. 
However, our finding that very little GPC5GAG mutant can be 
found in cilia leads us to speculate that the ciliary localization of 
GPC5 may be the result of its interaction with Ptc1. This possibil-
ity is also supported by our observation that GPC3, which does 
not interact with Ptc1 (Capurro et al., 2008), could not be detected 
in the cilia (Fig. 7 C). In this regard, it is important to note that 
the localization of GPC3 outside of the cilium is consistent with 
the ability of this glypican to compete for Hh with Ptc1 and, in this 
way, to inhibit Hh signaling. We also speculate that the small 
amount of GPC5GAG that was detected in the cilia is the re-
sult of overexpression in the transfected NIH 3T3 cells. It should 
be noted, on the other hand, that we could detect high levels of 
endogenous GPC5 in the cilia of RMS cells (Fig. 7 D).
We show here that the affinity of GPC5 for Shh is signifi-
cantly lower than that of GPC3. Furthermore, whereas the inter-
action of GPC3 with Shh is mediated mostly by the core protein 
(Capurro et al., 2008), GPC5 binds to Shh mainly through the 
HS chains. Although the lack of high affinity interaction be-
tween the core protein of GPC5 and Shh is somewhat un-
expected, it should be noted that the Shh-binding domain in GPC3 
has not been identified yet and that the two glypicans display 
only 50% identity. Based on these results, it is reasonable to 
speculate that the lower affinity of GPC5 for Shh may facilitate 
a productive interaction of this growth factor with Ptc1, whereas 
the high affinity interaction between GPC3 and Shh inhibits the 
engagement of Ptc1 by the ligand.
Because GPC5 is overexpressed in RMS, our finding that 
this glypican promotes the growth of RMS by stimulating Hh 
signaling may have clinical implications. Various inhibitors of 
Hh signaling are currently being tested in clinical trials as tools 
to treat several cancer types that display increased activation of 
the Hh signaling pathway (Rudin et al., 2009; Von Hoff et al., 
2009). Most of these Hh inhibitors target Smoothened, a key 
component of the Hh pathway. The results presented here sug-
gest that these inhibitors could also be used to treat RMS pa-
tients. Furthermore, if inhibitors of GPC5 activity can be found, 
a more specific targeting of Hh signaling in RMS could be 
achieved, avoiding, in this way, potential side effects of a gen-
eral inhibition of the Hh activity.
Materials and methods
Cell lines and plasmids
293T, NIH 3T3, and C2C12 cells were cultured in DME supplemented 
with 10% FBS. The RMS cell lines CW9019 and RH30 were grown in 
RPMI 1640 medium with 10% FBS. All cell lines were maintained at 37°C 
in a humidified atmosphere with 5% CO2. To prepare conditioned media, 
293T, NIH 3T3, or RH30 cells were transiently transfected with the indicated 
expression vectors, and culture medium was collected 72 h after transfec-
tion. ShhN-conditioned medium was generated by transfecting 293T cells 
with an Shh expression vector. The medium, which contained 2% serum, 
was collected 6 d after transfection. The multimeric ShhN peptide–conditioned 
medium was generated by transfecting the full-length Shh cDNA into 293T 
cells. The medium was collected after 48 h in serum-free conditions.
The full-length human GPC5 DNA was obtained from OriGene Tech-
nologies and cloned into pTracer (Invitrogen). A nonglycanated mutant of 
GPC5  (GPC5GAG)  was  generated  by  mutating  five  serine  residues 
(Ser
441, Ser
486, Ser
495, Ser
507, and Ser
509) to alanine by site-directed muta-
genesis. Mutations were verified by DNA sequencing. The GPC5-AP and 
GPC5GAG-AP vectors were prepared by inserting the human GPC5 and 703 Glypican-5 activates Hedgehog signaling • Li et al.
48 h before fixing for staining. Stained cells were photographed on a   
microscope (Axiovert 100M; Carl Zeiss, Inc.) equipped with a Plan Apo-
chromat (Carl Zeiss, Inc.) 100×/1.4 NA oil dichromic objective. Confocal 
images were generated using a scanning laser microscope (LSM 510 ver-
sion 3.2 SP2; Carl Zeiss, Inc.). Image analysis was performed using the 
ImageJ program (National Institutes of Health) as previously reported   
(Rohatgi et al., 2007). In brief, a mask, which was constructed by manu-
ally outlining cilia in the image of acetylated tubulin staining, was applied 
to GPC5/GPC5GAG-stained images to measure the fluorescence inten-
sity at cilia. The mean fluorescence intensity of other regions of the cell was 
obtained by measuring several representative regions on the cell by mov-
ing the mask. After subtracting the background from both aforementioned 
fluorescence intensities, the ratio of fluorescence intensity in the cilium to 
that outside of the cilium was calculated.
Online supplemental material
Fig. S1 shows a luciferase reporter assay in NIH 3T3 cells demonstrating 
that GPC5 stimulates both ShhN and full-length Shh signaling. Fig. S2 shows 
the disaccharide analysis of the HS chains of GPC3-AP and GPC5-AP puri-
fied from transiently transfected RH30 cells. Fig. S3 demonstrates that hep-
aran does not stimulate Shh-induced signaling as measured by a luciferase 
reporter assay in NIH 3T3 cells. Table S1 shows the kinetic parameters for 
the interaction of Shh with GPC5-AP. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.201008087/DC1.
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